Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

INSULIN Act; Insulin Out of Pocket Charges;


S. 148 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen. Amy Klobuchar (D-MN)


S. 142 - Preserve Access to Affordable Generics and Biosimilars Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen. Amy Klobuchar (D-MN)

S. 150 - Affordable Prescriptions for Patients Act of 2023
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. John Cornyn (R-TX)

S. 127 - Pharmacy Benefit Manager Transparency Act of 2023
A bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
Sponsor: Sen. Maria Cantwell (D-WA)

S. 954 - Affordable Insulin Now Act of 2023
A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals.
Sponsor: Sen. Raphael Warnock (D-GA)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

REL Data Standards; Ensuring Lasting Smiles Act; Addressing Workforce Shortages;
Telehealth payment parity requirements; Affordability; COVID commercialization; Affordable Care Act; Telehealth; Telehealth Expansion Act; Youth Mental Health; Maternal Health; Addressing Workforce Shortages; Maternal Health Equity; Site Neutrality Hospital Billing; Debt Ceiling;
Appropriations;


H.R. 485 Protecting Health Care for All Patients Act - Protecting Health Care for All Patients Act of 2023
To amend title XI of the Social Security Act to prohibit the use of quality-adjusted life years and similar measures in coverage and payment determinations under Federal health care programs.
Sponsor: Rep. Cathy McMorris Rodgers (R-WA-05)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Office of Management & Budget (OMB), Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Labor - Dept of (DOL)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicaid same-day billing; Medicare Advantage Advance Rate Notice; Medicare Advantage Prior Authorization Legislation; Provider Directory Accuracy; MA RADV Rule; Site Neutral Payments and Payment Accuracy; Site Neutral Payments and Payment Accuracy; UPCODE Act; RADV Rule &
Rate Notice; Medicare Advantage Advance Rate Notice; Medicaid Redeterminations;

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes